NCT01664598View on ClinicalTrials.gov

An Extension Study of WA19926 of the Long-Term Safety of Tocilizumab (RoActemra/Actemra) in Patients With Early Moderate to Severe Rheumatoid Arthritis

PHASE3CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2015

Conditions
Rheumatoid Arthritis
Interventions
DRUG

Tocilizumab

8 mg/kg administered intravenously (IV) every 4 weeks for 104 weeks

Trial Locations (12)

105203

Moscow

115522

Moscow

115682

Moscow

119049

Moscow

129327

Moscow

150030

Yaroslavl

195067

Saint Petersburg

300053

Tula

390011

Ryazan

394066

Voronezh

410002

Saratov

620102

Yekaterinburg

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT01664598 - An Extension Study of WA19926 of the Long-Term Safety of Tocilizumab (RoActemra/Actemra) in Patients With Early Moderate to Severe Rheumatoid Arthritis | Biotech Hunter | Biotech Hunter